/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

CALGARY, AB, March 12, 2026 /CNW/ - Seegnal Inc. (TSXV: SEGN) ("Seegnal" or the "Corporation"), a global leader in SaaS clinical division support solutions, announces that its market making services agreement dated September 24, 2025 ("Services Agreement") with Generation IACP Inc. ("GIACP"), previously announced on September 25, 2025, will be terminated effective March 25, 2026.

About Seegnal

Seegnal is a public company that aims to solve one of the top causes of death and injuries in the modern world – Adverse Drug Effects (ADEs). Seegnal's Clinical Decision Support system introduces a paradigm shift in the approach to this problem by implementing a new elevated Patient-Centric Standard. Seegnal's SaaS technology exclusively integrates at the point-of-care, unique patient-specific data like genetics, results of lab tests, ECG, smoking, allergies, food, gender, age, and the effects of many concomitant medications, while reducing the current alert load for clinicians by over 90%. In practice, clinicians using Seegnal eHealth complete their prescription workflow with limited interruption, saving time and fatigue. Similarly, patients enjoy more tailored medication and improved safety, leading to better quality of life, due to the precision of alerts with up to 98% accuracy. Institutions reported a reduction in admissions, medication consumption, and ample time savings in prescription renewals. Seegnal eHealth is marketing its SaaS-based platform in the State of Israel (where recently the Ministry of Health has adopted Seegnal's patient-specific standard as the new standard in governmental hospitals), the UAE, the United Kingdom, the United States, and Poland. The platform is currently a "standard of care" system for over 10,000 clinicians in Israel, used on a daily basis for prescribing medications to their patients.

See www.seegnal.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

The securities have not been and will not be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirement. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

SOURCE Seegnal Inc.